Schreiber, Robert D.

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 6,474

Cancer immunoediting: from immunosurveillance to tumor escape

Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 5,393

Neoantigens in cancer immunotherapy

Schumacher, T. N., & Schreiber, R. D. (2015) · Science

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 4,783

HOW CELLS RESPOND TO INTERFERONS

Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry

interferon and immune responsesCytokine Signaling Pathways and Interactions

Cited by 3,932

Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death

Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 3,720

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell

Cancer Immunotherapy and BiomarkersCancer, Hypoxia, and Metabolism

Cited by 3,331

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 2,896

Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity

Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science

Immunotherapy and Immune ResponsesT-cell and B-cell Immunology

Cited by 2,081

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,974

Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway

Meraz, M. A., White, J. M., Sheehan, K. C. F., Bach, E. A., Rodig, S. J., Dighe, A. S., Kaplan, D. H., Riley, J. K., Greenlund, A. C., Campbell, D., et al. (1996) · Cell

Cytokine Signaling Pathways and Interactionsinterferon and immune responses

Cited by 1,656

Interferons, immunity and cancer immunoediting

Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology

interferon and immune responsesImmunotherapy and Immune Responses

Cited by 1,617

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,471

Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice

Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences

interferon and immune responsesCancer Immunotherapy and Biomarkers

Cited by 1,465

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 1,200

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine

Immunotherapy and Immune Responsesinterferon and immune responses

Cited by 1,081

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine

interferon and immune responsesImmunotherapy and Immune Responses

Cited by 1,042

MHC-II neoantigens shape tumour immunity and response to immunotherapy

Alspach, E., Lussier, D. M., Miceli, A. P., Kizhvatov, I., DuPage, M., Luoma, A. M., Meng, W., Lichti, C. F., Esaulova, E., Vomund, A. N., et al. (2019) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 846

Recombinant IL-12 administration induces tumor regression in association with IFN- gamma production.

Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., et al. (1994) · The Journal of Immunology

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 780

Persistent LCMV infection is controlled by blockade of type I interferon signaling

Teijaro, J. R., Ng, C., Lee, A. M., Sullivan, B. M., Sheehan, K. C. F., Welch, M., Schreiber, R. D., Carlos de la Torre, J., & Oldstone, M. B. A. (2013) · Science

interferon and immune responsesVirology and Viral Diseases

Cited by 755

Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNγ receptors

Dighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994) · Immunity

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 663

TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy

Molgora, M., Esaulova, E., Vermi, W., Hou, J., Chen, Y., Luo, J., Brioschi, S., Bugatti, M., Omodei, A. S., Ricci, B., et al. (2020) · Cell

Cancer Immunotherapy and BiomarkersImmune cells in cancer

Cited by 656

cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity

Ferris, S. T., Durai, V., Wu, R., Theisen, D. J., Ward, J. P., Bern, M. D., Davidson, J. T., Bagadia, P., Liu, T., Briseño, C. G., et al. (2020) · Nature

Immunotherapy and Immune ResponsesT-cell and B-cell Immunology

Cited by 611

Stat1-dependent and -independent pathways in IFN-γ-dependent signaling

Ramana, C. V., Gil, M. P., Schreiber, R. D., & Stark, G. R. (2002) · Trends in Immunology

Cytokine Signaling Pathways and Interactionsinterferon and immune responses

Cited by 555

Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction

Wells, D. K., van Buuren, M. M., Dang, K. K., Hubbard-Lucey, V. M., Sheehan, K. C. F., Campbell, K. M., Lamb, A., Ward, J. P., Sidney, J., Blazquez, A. B., et al. (2020) · Cell

vaccines and immunoinformatics approachesCancer Immunotherapy and Biomarkers

Cited by 538